Introduction: Only ~ 50% of hypertensive patients will respond to treatment.
Objective: This pilot study aims to identify clinical and metabolite markers that predict response to lisinopril.
Methods: Hypertensive patients (n = 45) received lisinopril (10 mg) at their baseline visit. Blood pressures were reevaluated one week later. Responders to lisinopril (n = 19) were defined by a 10% decline in systolic blood pressure. Plasma metabolites were evaluated with mass spectrometry.
Results: BMI (p = 0.009), GFR (p = 0.015) and 2-oxoglutarate were included in a logistic regression model to predict response to lisinopril.
Conclusions: Further validation cohorts are needed to confirm the predictive values of these clinical and metabolic markers.
Keywords: 2-Oxoglutarate; ACE/ARB; Hypertension; Lisinopril; Personalized medicine; Precision medicine.